Showing 311-320 of 1917 results for "".
Permission Slips: What You May Be Doing Wrong
https://practicaldermatology.com/topics/practice-management/permission-slips-what-you-may-be-doing-wrong/19540/Mathew Avram, MD, JD shares insights on legal protections for physicians and patients and offers tips for protecting dermatologists against malpractice. He covers common misunderstandings, including missteps associated with informed consent.Keeping Up with MACRA: The Right Partner Can Help
https://practicaldermatology.com/topics/practice-management/keeping-up-with-macra-the-right-partner-can-help/20380/Revised MACRA requirements go into effect in January. The right technology partner can ease the transition.The Sernivo Formulation
https://practicaldermatology.com/topics/general-topics/the-sernivo-formulation-/18250/SERNIVO (betamethasone dipropionate) Spray, 0.05% is formulated to provide fast and powerful treatment for adult patients with mild to moderate plaque psoriasis. Dr. Jeffrey S. Fromowitz guides viewers through the mechanisms of SERNIVO in these video chapters.Updates from the AAD Annual Meeting in San Diego
https://practicaldermatology.com/topics/practice-management/updates-from-the-aad-annual-meeting-in-san-diego/18332/From cosmetic interventions to therapeutic breakthroughs for common dermatoses, and new technologies for practice, the latest innovations take center stage at the 2018 Annual Meeting of the American Academy of Dermatology. Joel L. Cohen, MD; Yolanda Lenzy, MD, MPH; Junko Takeshita, MD, PhD, MSCE; anRe-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaRevance Data, AD Updates, FDA Actions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-revance-data-ad-updates-fda-actions/18463/A US District Court judge blocks Stratus Pharmaceuticals of Miami and Sonar Products of Carlstadt, NJ from selling substandard dermatological products. Newly identified mutations in a gene called CARD11 may lead to atopic dermatitis. Surprising new evidence suggests atopic dermatitis is associated wWhat's Old Is New
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/old-new-2017/18512/Besides new fillers and better device-based combinations, Joel L. Cohen, MD says that 2017 will bring new data on some existing interventions that may improve aesthetic procedures. Watch the video memo now.Neuromodulators in Medical Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neuromodulators-in-medical-dermatology/18520/Physicians are exploring the effects of botulinum toxins on several medical dermatology conditions. Erin Gilbert, MD talks to Joel Cohen, MD about her experience treating rosacea, and discusses the need for better randomized trials to explore treatment options.CSF 2016 Highlights from the Founder
https://practicaldermatology.com/topics/skin-cancer-photoprotection/csf-2016-highlights-from-the-founder/18711/Cosmetic Surgery Forum Founder and Practical Dermatology® Chief Surgical Editor Joel Schlessinger, MD talks about CSF 2016. What sets the meeting apart? How has it evolved in 8 years? And what did he learn from this year's program? Find out.Golden Achievement: Dr. Michael Gold on Lifetime Award at CSF 2016
https://practicaldermatology.com/topics/practice-management/golden-achievement-dr-michael-gold-on-lifetime-award-at-csf-2016/18712/Michael H. Gold, MD was recognized December 2016 at the Cosmetic Surgery Forum in Las Vegas with the Lifetime Contribution to Aesthetics Award by CSF Founder Joel Schlessinger, MD. Speaking about the award, Dr. Gold shares his perspective as a global educator and practitioner (Dr. Gold cofounded the